Abstracts tagged "Patient reported outcomes"

Abstract Number: 0155 • ACR Convergence 2020
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
William Nowell¹, Elaine Karis², Kelly Gavigan³, Laura Stradford³, Scott Stryker², Huifeng Yun⁴, Shilpa Venkatachalam⁵, Gregory Kricorian², Lang Chen⁴, Hong Zhao⁶, Fenglong Xie⁶ and Jeffrey R Curtis⁴, ¹Global Healthy Living Foundation, New York City, NY, ²Amgen Inc., Thousand Oaks, CA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…
Abstract Number: 0320 • ACR Convergence 2020
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Tal Gazitt¹, Muhanad Abu Elhija¹, Amir Haddad¹, Idit Lavi¹, Muna Elias¹ and Devy Zisman¹, ¹Carmel Hospital, Haifa, Israel
Background/Purpose: To assess the implementation of the “Treat-to-Target” (T2T) concept using validated composite disease activity scores in daily management of psoriatic arthritis (PsA).Methods: A retrospective…
Abstract Number: 0583 • ACR Convergence 2020
Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Santos Castañeda¹, Esther Francisca Vicente-Rabaneda², Mar Llamas-Velasco³, Javier Sánchez-Pérez³, José Pardo⁴, Rita Cabeza-Martínez⁵, Mercedes Miranda-Fontes⁶, Juan Márquez⁷, Jaime Calvo-Alén⁸, Susana Armesto⁹, Isabel Belinchón¹⁰, Alejandro Gómez¹¹, María Dolores Miranda¹², Silvia Martínez-Pardo¹³, Leticia Merino Melendez¹⁴, Miguel Ángel Casado¹⁵, María Yébenes¹⁵ and Araceli Casado¹⁵, ¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴H.G.U. Santa Lucía, Cartagena, Murcia, Spain, ⁵H.U. Puerta de Hierro Majadahonda, Madrid, Madrid, Spain, ⁶H.U. Río Hortega, Valladolid, Valladolid, Castilla y Leon, Spain, ⁷H.G. Jerez de la Frontera, Cádiz, Andalucia, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹H.U. Marqués de Valdecilla, Santander, Cantabria, Spain, ¹⁰H.G.U. Alicante, Alicante, Comunidad Valenciana, Spain, ¹¹H.U. Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain, ¹²H.G. San Agustín de Linares, Jaen, Andalucia, Spain, ¹³H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ¹⁴H. San Pedro, Logroño, Spain, ¹⁵Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Madrid, Spain
Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and…
Abstract Number: 1110 • ACR Convergence 2020
Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function
Holly Philpott¹, Trevor Birmingham², Ryan Pinto², Dominique Arsenault², Codie Primeau², Edward Vasarhelyi³, Steven MacDonald³, Brent Lanting³ and Tom Appleton⁴, ¹Western University, London, ON, Canada, ²Western University, London, Canada, ³London Health Sciences Centre, London, Canada, ⁴The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Signs of inflammation in knee osteoarthritis (OA), including synovitis, are associated with worse clinical outcomes such as increased pain, risk of progression, and future…
Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1457 • ACR Convergence 2020
Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis
Sai kumar Dunga¹, Chengappa G Kavadichanda² and VS Negi², ¹Jawaharlal institute of postgraduate medical education and research, puducherry, India, ²Jawaharlal institute of postgraduate medical education and research, Puducherry, Puducherry, India
Background/Purpose: Inflammatory myositis are heterogenous group of diseases affecting skeletal muscles and multiple different organs. Assessing improvement in disease activity is done by Manual muscle…
Abstract Number: 1725 • ACR Convergence 2020
An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
Abstract Number: 1985 • ACR Convergence 2020
Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
Chiara Trincianti¹, E. H. Pieter Van Dijkhuizen², Serena Calandra³, Helga Sanner⁴, Tamas Constantin⁵, Troels Herlin⁶, Marco Cattalini⁷, Flavio Sztajnbok⁸, Despoina Maritsi⁹, Nicolino Ruperto¹⁰, Angelo Ravelli¹¹ and Alessandro Consolaro¹¹, ¹Istituto Giannina Gaslini, Genova, Liguria, Italy, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³IRCCS Istituto Giannina Gaslini, Genoa, Liguria, Italy, ⁴Oslo University Hospital, Oslo, Norway, ⁵Semmelweis University, Budapest, Hungary, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷Università di Brescia, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹National and Kapodistrian University of Athens, Athens, Greece, ¹⁰Istituto Giannina Gaslini, Genova, Italy, ¹¹Università degli Studi di Genova, Genoa, Italy
Background/Purpose: In the last years, the interest in the assessment of parent- and child-reported outcomes (PCROs) in paediatric rheumatic diseases is gaining increasing importance. These…
Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Emily Sirotich¹, Kevin Kennedy², Salman Surangiwala³, Teresa Semalulu¹, Maggie Larche¹, Jean Liew⁴, Zachary Wallace⁵, Philip Robinson⁶, Rebecca Grainger⁷, Jeffrey Sparks⁸, Julia Simard⁹, Jinoos Yazdany¹⁰, Monique Gore-Massy¹¹, Richard Howard¹², Mitchell Levine² and Jonathan Hausmann¹³, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴University of Washington, Seattle, WA, ⁵Massachusetts General Hospital, Newton, MA, ⁶University of Queensland, Herston, Queensland, Australia, ⁷University of Otago, Wellington, New Zealand, ⁸Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁹Stanford Medicine, Stanford, CA, ¹⁰UCSF, San Francisco, CA, ¹¹Lupus Foundation of America, Brooklyn, NY, ¹²Spondylitis Association of America, Van Nuys, CA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…
Abstract Number: 0157 • ACR Convergence 2020
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
Cristina Valero¹, Noelia Garcia¹, Juan Pablo Baldivieso², Ana Ortiz³, Sebastian Rodriguez² and Isidoro González-Álvaro³, ¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²Hospital de La Princesa, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: In recent years there is increasing evidence of the relevance of including the assessment of the different aspects of rheumatoid arthritis (RA) from the…
Abstract Number: 0323 • ACR Convergence 2020
Residual Symptoms in Patients with PsA Who Are in Very Low Disease Activity According to Physician Assessments
Alexis Ogdie¹, Soumya Reddy², Ethan Craig¹, Jose Scher³, Yvonne Lee⁴, Jessica Walsh⁵ and M. Elaine Husni⁶, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York City, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Discrepancy between patient and provider assessments of disease activity is well described in psoriatic arthritis (PsA) and other inflammatory arthritides. Patients often have low…
Abstract Number: 0608 • ACR Convergence 2020
Patient and Parent Perspectives in a Academic Pediatric Rheumatology Transition Clinic
Rebecca Overbury¹, Tracy Frech², John Bohnsack³, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki⁴ and Aimee Hersh⁴, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: In November 2018 we initiated a transition clinic called ACCORD (Adult Center for Childhood Onset Rheumatic Disease). Our unique structure integrates an adult rheumatologist…
Abstract Number: 1125 • ACR Convergence 2020
Patient Reported Impact of Lupus on Quality of Life
Beth Schneider¹, ¹MyHealthTeams, San Francisco, CA
Background/Purpose: Research was undertaken to better understand how people living with lupus describe its sum total impact on their lives including work, challenges with relationships…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1460 • ACR Convergence 2020
“Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a Voice-Enabled Smartphone App to Virtually Monitor Disease Activity and Collect ePROs in Rheumatoid Arthritis
Meredith Murray¹, Stephen Penney², Adam Landman³, Josephine Elias², Emma Richard⁴, Bert Hartog⁴ and Daniel H. Solomon⁵, ¹Brigham and Women's Hospital, Medfield, MA, ²Partners Healthcare, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Janssen Research & Development, LLC, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic disease that involves frequent patient-provider interaction and self-monitoring, both integral to successful disease management. We developed a novel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].